Advanced Enzyme Technologies has reported strong financial results for the fiscal year ended March 31, 2026. The company achieved a consolidated annual revenue of ₹7,457.57 million and a net profit after tax of ₹1,736.08 million. Reflecting its healthy financial position, the board has recommended a final dividend of ₹1.35 per share for the 2025-26 fiscal year, subject to shareholder approval at the upcoming 37th Annual General Meeting.
Financial Performance Highlights
For the financial year 2025-26, Advanced Enzyme Technologies delivered a solid performance with total consolidated income reaching ₹7,805.89 million, up from ₹6,699.51 million in the previous year. The consolidated net profit attributable to shareholders for the year stood at ₹1,687.19 million, compared to ₹1,311.15 million in the prior fiscal year. The company’s basic earnings per share (EPS) for the year reached ₹15.08.
Strategic Dividend Recommendation
Demonstrating its commitment to creating shareholder value, the board of directors has recommended a final dividend of 67.5%, equivalent to ₹1.35 per equity share on a face value of ₹2 per share. The declaration remains subject to approval by shareholders at the 37th Annual General Meeting. The company has decided to defer any interim dividend to maintain capital flexibility for future strategic corporate actions.
Leadership and Governance Updates
The board has approved the reappointment of Mr. Mukund Madhusudan Kabra as Whole-time Director for a new 5-year term effective from April 1, 2027. Additionally, Mr. Pradip Bhailal Shah has been appointed as an Additional Director (Independent) for a 5-year term starting June 12, 2026. Furthermore, M S K A & Associates LLP has been reappointed as the Statutory Auditors for a second consecutive five-year term.
Operational Milestones
The company continues to expand its footprint and streamline operations. Notably, the board approved the allotment of 49,350 equity shares under the Employee Stock Options Scheme 2022. This move has increased the company’s paid-up share capital to ₹22,39,52,300, comprising 11,19,76,150 equity shares. The business remains focused on its core segment of manufacturing and selling enzymes, while effectively managing risks and regulatory compliance.
Source: BSE
